Genomics and the efficacy of aspirin in the treatment of cerebrovascular disease

Current Treatment Options in Cardiovascular Medicine

Volumn 11, Issue 3, 2009, Pages 191-200

  Cavallari, Larisa H ^a   Momary, Kathryn M ^b  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; APOLIPOPROTEIN A; CLOPIDOGREL; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; DIPYRIDAMOLE; GLYCOPROTEIN; INDOMETACIN; MEMBRANE PROTEIN; PLACEBO; PLATELET ENDOTHELIAL AGGREGATION RECEPTOR 1; PURINERGIC P2Y12 RECEPTOR; THIENOPYRIDINE DERIVATIVE; UNCLASSIFIED DRUG;

BLEEDING; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DISEASE COURSE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG RESPONSE; DRUG TREATMENT FAILURE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOMICS; GENOTYPE; HAPLOTYPE; HEART INFARCTION; HERITABILITY; HIGH RISK PATIENT; HUMAN; MONOTHERAPY; MORTALITY; PHARMACOGENETICS; PRIMARY PREVENTION; PROMOTER REGION; REVIEW; RISK MANAGEMENT; RISK REDUCTION; SECONDARY PREVENTION; SINGLE NUCLEOTIDE POLYMORPHISM; THROMBOCYTE AGGREGATION INHIBITION;

EID: 65549125934     PISSN: 10928464     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11936-009-0020-x     Document Type: Review

References (36)

1. The Antiplatelet Trialists' Collaboration: Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002, 324:71-86.
2. Bartolucci AA, Howard G: Meta-analysis of data from the six primary prevention trials of cardiovascular events using aspirin. Am J Cardiol 2006, 98:746-750.
3. Patrono C, Baigent C, Hirsh J, Roth G: Antiplatelet drugs: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008, 133:199S-233S.
4. Becker RC, Meade TW, Berger PB, et al.: The primary and secondary prevention of coronary artery disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008, 133:776S-814S.
5. Pearson TA, Blair SN, Daniels SR, et al.: AHA Guidelines for Primary Prevention of Cardiovascular Disease and Stroke: 2002 Update: Consensus Panel Guide to Comprehensive Risk Reduction for Adult Patients Without Coronary or Other Atherosclerotic Vascular Diseases. American Heart Association Science Advisory and Coordinating Committee. Circulation 2002, 106:388-391.
6. Campbell CL, Steinhubl SR: VarDability in response to aspirin: do we understand the clinical relevance? J Thromb Haemost 2005, 3:665-669.
7. Mueller MR, Salat A, Stangl P, et al.: Variable platelet response to low-dose ASA and the risk of limb deterioration in patients submitted to peripheral arterial angioplasty. Thromb Haemost 1997, 78:1003-1007.
8. Gum PA, Kottke-Marchant K, Poggio ED, et al.: Profile and prevalence of aspirin resistance in patients with cardiovascular disease. Am J Cardiol 2001, 88:230-235.
9. Gum PA, Kottke-Marchant K, Welsh PA, et al.: A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol 2003, 41:961-965.
10. Eikelboom JW, Hirsh J, Weitz JI, et al.: Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation 2002, 105:1650-1655.
11. Angiolillo DJ, Bernardo E, Sabate M, et al.: Impact of platelet reactivity on cardiovascular outcomes in patients with type 2 diabetes mellitus and coronary artery disease. J Am Coll Cardiol 2007, 50:1541-1547.
12. Chen WH, Cheng X, Lee PY, et al.: Aspirin resistance and adverse clinical events in patients with coronary artery disease. Am J Med 2007, 120:631-635.
13. Faraday N, Yanek LR, Mathias R, et al.: Heritability of platelet responsiveness to aspirin in activation pathways directly and indirectly related to cyclooxygenase-1. Circulation 2007, 115:2490-2496.
14. Cooke GE, Bray PF, Hamlington JD, et al.: P1A2 polymorphism and efficacy of aspirin. Lancet 1998, 351:1253.
15. Michelson AD, Furman MI, Goldschmidt-Clermont P, et al.: Platelet GP IIIa P1(A) polymorphisms display different sensitivities to agonists. Circulation 2000, 101:1013-1018.
16. Andrioli G, Minuz P, Solero P, et al.: Defective platelet response to arachidonic acid and thromboxane A(2) in subjects with P1(A2) polymorphism of beta(3) subunit (glycoprotein IIIa). Br J Haematol 2000, 110:911-918.
17. Ridker PM, Hennekens CH, Schmitz C, et al.: PIA1/A2 polymorphism of platelet glycoprotein IIIa and risks of myocardial infarction, stroke, and venous thrombosis. Lancet 1997, 349:385-388.
18. Undas A, Brummel K, Musial J, et al.: P1(A2) polymorphism of beta(3) integrins is associated with enhanced thrombin generation and impaired antithrombotic action of aspirin at the site of microvascular injury. Circulation 2001, 104:2666-2672.
19. Goodman T, Ferro A, Sharma P: PharAacogenetics of aspirin resistance: a comprehensive systematic review. Br J Clin Pharmacol 2008, 66:222-232.
20. Lee CR, Bottone FG Jr, Krahn JM, et al.: Identification and functional characterization of polymorphisms in human cyclooxygenase-1 (PTGS1). Pharmacogenet Genomics 2007, 17:145-160.
21. Halushka MK, Walker LP, Halushka PV: Genetic variation in cyclooxygenase 1: Effects on response to aspirin. Clin Pharmacol Ther 2003, 73:122-130.
22. Lee CR, North KE, Bray MS, et al.: Cyclooxygenase polymorphisms and risk of cardiovascular events: The Atherosclerosis Risk in Communities (ARIC) study. Clin Pharmacol Ther 2008, 83:52-60.
23. Baker CS, Hall RJ, Evans TJ, et al.: Cyclooxygenase-2 is widely expressed in atherosclerotic lesions affecting native and transplanted human coronary arteries and colocalizes with inducible nitric oxide synthase and nitrotyrosine particularly in macrophages. Arterioscler Thromb Vasc Biol 1999, 19:646-655.
24. Papafili A, Hill MR, Brull DJ, et al.: Common promoter variant in cyclooxygenase-2 represses gene expression: Evidence of role in acute-phase inflammatory response. Arterioscler Thromb Vasc Biol 2002, 22: 1631-1636.
25. The ARIC Investigators: The Atherosclerosis Risk in Communities (ARIC) Study: Design and objectives. Am J Epidemiol 1989, 129:687-702.
26. Clappers N, van Oijen MG, Sundaresan S, et al.: The C50T polymorphism of the cyclooxygenase-1 gene and the risk of thrombotic events during low-dose therapy with acetyl salicylic acid. Thromb Haemost 2008, 100:70-75.
27. Herrera-Galeano JE, Becker DM, Wilson AF, et al.: A novel variant in the platelet endothelial aggregation receptor-1 gene is associated with increased platelet aggregability. Arterioscler Thromb Vasc Biol 2008, 28:1484-1490.
28. Cavallari U, Trabetti E, Malerba G, et al.: Gene sequence variations of the platelet P2Y12 receptor are associated with coronary artery disease. BMC Med Genet 2007, 8:59.
29. Ziegler S, Schillinger M, Funk M, et al.: Association of a functional polymorphism in the clopidogrel target receptor gene, P2Y12, and the risk for ischemic cerebrovascular events in patients with peripheral artery disease. Stroke 2005, 36:1394-1399.
30. Bierend A, Rau T, Maas R, et al.: P2Y12 polymorphisms and antiplatelet effects of aspirin in patients with coronary artery disease. Br J Clin Pharmacol 2008, 65:540-547.
31. Marcovina SM, Koschinsky ML: A critical evaluation of the role of Lp(a) in cardiovascular disease: Can Lp(a) be useful in risk assessment? Semin Vasc Med 2002, 2:335-344.
32. Suk Danik J, Rifai N, Buring JE, Ridker PM: Lipoprotein(a), measured with an assay independent of apolipoprotein(a) isoform size, and risk of future cardiovascular events among initially healthy women. JAMA 2006, 296:1363-1370.
33. Luke MM, Kane JP, Liu DM, et al.: A polymorphism in the protease-like domain of apolipoprotein(a) is associated with severe coronary artery disease. Arterioscler Thromb Vasc Biol 2007, 27:2030-2036.
34. Shiffman D, O'Meara ES, Bare LA, et al.: Association of gene variants with incident myocardial infarction in the Cardiovascular Health Study. Arterioscler Thromb Vasc Biol 2008, 28:173-179.
35. Chasman DI, Shiffman D, Zee RY, et al.: Polymorphism in the apolipoprotein(a) gene, plasma lipoprotein(a), cardiovascular disease, and low-dose aspirin therapy. Atherosclerosis 2008 Jul 26 (E-pub ahead of print).
36. Cavallari LH, Helgason CM, Brace LD, et al.: Sex difference in the antiplatelet effect of aspirin in patients with stroke. Ann Pharmacother 2006, 40:812-817.